Bibliometric analysis of monoclonal antibodies for atherosclerosis

References

• Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözoğlu L, Lewis EF. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. doi:10.1038/s41572-019-0106-z.
   PubMed Web of Science ®Google Scholar
• Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, Fowkes FGR, Fowkes FJI, Rudan I. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health. 2020;8(5):e721–15. doi:10.1016/S2214-109X(20)30117-0.
   PubMed Web of Science ®Google Scholar
• Koeckerling D, Raguindin PF, Kastrati L, Bernhard S, Barker J, Quiroga Centeno AC, Raeisi-Dehkordi H, Khatami F, Niehot C, Lejay A, et al. Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis. Eur Heart J. 2023;44(11):935–50. doi:10.1093/eurheartj/ehac722.
   PubMed Web of Science ®Google Scholar
• Port SC. High-dose statins and atherosclerosis regression. JAMA. 2006;296(15):1836; author reply 1837. doi:10.1001/jama.296.15.1836-a.
   PubMedGoogle Scholar
• Lee Y-J, Cho JY, You SC, Lee Y-H, Yun KH, Cho Y-H, Shin W-Y, Im SW, Kang WC, Park Y, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023;44(11):972–83. doi:10.1093/eurheartj/ehac709.
   PubMed Web of Science ®Google Scholar
• Pedicino D, Volpe M. Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape. Eur Heart J. 2022;43(41):4227–8. doi:10.1093/eurheartj/ehac502.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373–84. doi:10.1001/jama.2016.16951.
   PubMed Web of Science ®Google Scholar
• Ma J, Luo J, Sun Y, Zhao Z. Cytokines associated with immune response in atherosclerosis. Am J Transl Res. 2022;14:6424–44.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science. 1991;252(5013):1657–62. doi:10.1126/science.2047874.
   PubMed Web of Science ®Google Scholar
• Bernelot Moens SJ, Neele AE, Kroon J, van der Valk FM, Van den Bossche J, den Bossche J V, Hoogeveen RM, Schnitzler JG, Baccara-Dinet MT, Manvelian G, et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Eur Heart J. 2017;38(20):1584–93. doi:10.1093/eurheartj/ehx002.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Singh I, Layhadi JA, Ito C, Karamani A, Kouser L, Sharif H, Tang J, Handijiev S, Parkin RV, et al. Passive prophylactic administration with a single dose of anti–fel d 1 monoclonal antibodies REGN1908–1909 in cat allergen–induced allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med. 2021;204(1):23–33. doi:10.1164/rccm.202011-4107OC.
   PubMed Web of Science ®Google Scholar
• Manta C-P, Leibing T, Friedrich M, Nolte H, Adrian M, Schledzewski K, Krzistetzko J, Kirkamm C, David Schmid C, Xi Y, et al. Targeting of scavenger receptors stabilin-1 and stabilin-2 ameliorates atherosclerosis by a plasma proteome switch mediating monocyte/macrophage suppression. Circulation. 2022;146(23):1783–99. doi:10.1161/CIRCULATIONAHA.121.058615.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060–9. doi:10.1016/S0140-6736(21)00520-1.
   PubMed Web of Science ®Google Scholar
• Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014;65(1):417–31. doi:10.1146/annurev-med-022613-090402.
   PubMedGoogle Scholar
• Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107. doi:10.1056/NEJMoa1801174.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. doi:10.1056/NEJMoa1615664.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, López JAG, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109–19. doi:10.1161/CIRCULATIONAHA.122.061620.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531–40. doi:10.1016/j.jacc.2014.03.018.
   PubMed Web of Science ®Google Scholar
• Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–8. doi:10.1016/j.jacc.2014.03.019.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, Khilla N, Hamlin R, Pordy R, Dong Y, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307–19. doi:10.1056/NEJMoa2031049.
   PubMed Web of Science ®Google Scholar
• Markham A. Evinacumab: first approval. Drugs. 2021;81(9):1101–5. doi:10.1007/s40265-021-01516-y.
   PubMed Web of Science ®Google Scholar
• Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D’Aco K, Fernandez A, Wache-Mainier C, et al. TET2 -driven clonal hematopoiesis and response to canakinumab. JAMA Cardiol. 2022;7(5):521–8. doi:10.1001/jamacardio.2022.0386.
   PubMed Web of Science ®Google Scholar
• Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns R-J, Ondracek AS, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771–81. doi:10.1001/jama.2022.5218.
   PubMed Web of Science ®Google Scholar
• Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29–36. doi:10.1016/S0140-6736(12)60771-5.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, Ridker PM, MacFadyen JG, Everett BM, Libby P, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–28. doi:10.1016/S0140-6736(17)32814-3.
   PubMed Web of Science ®Google Scholar
• Dimmitt SB, Stampfer HG, Warren JB. The pharmacodynamic and clinical trial evidence for statin dose. Br J Clin Pharmacol. 2018;84(6):1128–35. doi:10.1111/bcp.13539.
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, Gipe D. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8(6):554–61. doi:10.1016/j.jacl.2014.09.007.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682–9.e1. doi:10.1016/j.ahj.2014.07.028.
   PubMed Web of Science ®Google Scholar
• Wei N, Hu Y, Liu G, Li S, Yuan G, Shou X, Zhang X, Shi J, Zhai H. A bibliometric analysis of familial hypercholesterolemia from 2011 to 2021. Curr Probl Cardiol. 2023;48(7):101151. doi:10.1016/j.cpcardiol.2022.101151.
   PubMed Web of Science ®Google Scholar
• Yao Z, Lin Z, Wu W. Global research trends on immunotherapy in cancer: a bibliometric analysis. Hum Vaccin Immunother. 2023;19(2):2219191. doi:10.1080/21645515.2023.2219191.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. doi:10.1056/NEJMoa1707914.
   PubMed Web of Science ®Google Scholar
• Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res. 2014;114(11):1743–56. doi:10.1161/CIRCRESAHA.113.301145.
   PubMed Web of Science ®Google Scholar
• Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344(8925):793–5. doi:10.1016/S0140-6736(94)92346-9.
   PubMed Web of Science ®Google Scholar
• Leibundgut G, Witztum JL, Tsimikas S. Oxidation-specific epitopes and immunological responses: translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol. 2013;13(2):168–79. doi:10.1016/j.coph.2013.02.005.
   PubMed Web of Science ®Google Scholar
• Ramms B, Patel S, Sun X, Pessentheiner AR, Ducasa GM, Mullick AE, Lee RG, Crooke RM, Tsimikas S, Witztum JL, et al. Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering. JCI Insight. 2022;7(13):e158414. doi:10.1172/jci.insight.158414.
   PubMed Web of Science ®Google Scholar
• Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res. 2018;122(12):1722–40. doi:10.1161/CIRCRESAHA.118.311362.
   PubMed Web of Science ®Google Scholar
• Ridker PM. From C-Reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–56. doi:10.1161/CIRCRESAHA.115.306656.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T, CANTOS Pilot Investigative Group. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739–48. doi:10.1161/CIRCULATIONAHA.112.122556.
   PubMed Web of Science ®Google Scholar
• Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61(1):22–32. doi:10.1016/S1734-1140(09)70004-0.
   PubMed Web of Science ®Google Scholar
• Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27(1):55–62. doi:10.1093/intimm/dxu102.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, Dunbar RL, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211–21. doi:10.1056/NEJMoa1612790.
   PubMed Web of Science ®Google Scholar
• Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004;109(17):2046–9. doi:10.1161/01.CIR.0000127953.98131.ED.
   PubMed Web of Science ®Google Scholar
• Groenen AG, Halmos B, Tall AR, Westerterp M. Cholesterol efflux pathways, inflammation, and atherosclerosis. Crit Rev Biochem Mol Biol. 2021;56(4):426–39. doi:10.1080/10409238.2021.1925217.
   PubMed Web of Science ®Google Scholar
• Riad Shams SM, Vrontis D, Chaudhuri R, Chavan G, Czinkota MR. Stakeholder engagement for innovation management and entrepreneurial development: a meta-analysis. J Bus Res. 2020;119:67–86. doi:10.1016/j.jbusres.2020.08.036.
   PubMed Web of Science ®Google Scholar
• Santos RD, Ruzza A, Hovingh GK, Stefanutti C, Mach F, Descamps OS, Bergeron J, Wang B, Bartuli A, Buonuomo PS, et al. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022;10(10):732–40. doi:10.1016/S2213-8587(22)00221-2.
   PubMed Web of Science ®Google Scholar
• Villatoro A, Cuminetti V, Bernal A, Torroja C, Cossío I, Benguría A, Ferré M, Konieczny J, Vázquez E, Rubio A, et al. Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation. Nat Commun. 2023;14(1):12. doi:10.1038/s41467-022-35700-9.
   PubMed Web of Science ®Google Scholar
• Stokes KY, Granger DN. The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolaemia? J Physiol. 2005;562(3):647–53. doi:10.1113/jphysiol.2004.079640.
   PubMed Web of Science ®Google Scholar
• Baumer Y, McCurdy S, Weatherby TM, Mehta NN, Halbherr S, Halbherr P, Yamazaki N, Boisvert WA. Hyperlipidemia-induced cholesterol crystal production by endothelial cells promotes atherogenesis. Nat Commun. 2017;8(1):1129. doi:10.1038/s41467-017-01186-z.
   PubMedGoogle Scholar
• Cardoso D, Perucha E. Cholesterol metabolism: a new molecular switch to control inflammation. Clin Sci (Lond). 2021;135(11):1389–408. doi:10.1042/CS20201394.
   PubMed Web of Science ®Google Scholar
• Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative stress in atherosclerosis. Curr Atheroscler Rep. 2017;19(11):42. doi:10.1007/s11883-017-0678-6.
   PubMed Web of Science ®Google Scholar
• Mitra S, Deshmukh A, Sachdeva R, Lu J, Mehta JL. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci. 2011;342(2):135–42. doi:10.1097/MAJ.0b013e318224a147.
   PubMed Web of Science ®Google Scholar
• Gialeli C, Shami A, Gonçalves I. Extracellular matrix: paving the way to the newest trends in atherosclerosis. Curr Opin Lipidol. 2021;32(5):277–85. doi:10.1097/MOL.0000000000000775.
   PubMed Web of Science ®Google Scholar
• Simões G, Pereira T, Caseiro A. Matrix metaloproteinases in vascular pathology. Microvasc Res. 2022;143:104398. doi:10.1016/j.mvr.2022.104398.
   PubMed Web of Science ®Google Scholar
• Wirka RC, Wagh D, Paik DT, Pjanic M, Nguyen T, Miller CL, Kundu R, Nagao M, Coller J, Koyano TK, et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. Nat Med. 2019;25(8):1280–9. doi:10.1038/s41591-019-0512-5.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, et al. Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol. 2018;72(17):2012–21. doi:10.1016/j.jacc.2018.06.078.
   PubMed Web of Science ®Google Scholar